Tango Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Malte Peters
- Full Time Employees
- 155
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Binney Street Boston MA United States of America 02142
- IPO Date
- Sep 3, 2020
- CIK
- 0001819133
- Website
- tangotx.com
- Similar Companies
- Business
- Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company that discovers and develops precision medicines targeting cancer vulnerabilities, with a focus on mutant-selective and tumor-specific programs. The company offers a pipeline of novel small-molecule therapeutics, including TNG456 (first-in-class PRMT5-methyltransferase inhibitor for MTAP-deleted tumors), TNG348 (first-in-class MTA-cooperative PRMT5 inhibitor for solid tumors), TNG908 (brain penetrant LSD1 inhibitor for small cell lung cancer), and earlier-stage programs such as TNG462 (PRMT5 inhibitor for splicing factor mutant cancers) and discovery-stage assets targeting p53 and MRE11; these programs leverage the company's proprietary precision oncology platform combining bioinformatics, functional genomics, and chemistry to identify tumor cell dependencies. Tango Therapeutics operates primarily in the United States, with headquarters in Boston, Massachusetts, founded in 2019. Recent developments include the dosing of the first patient in the Phase 1/2 clinical trial of TNG348 in October 2024, positive initial data from the Phase 1/2 trial of TNG456 presented at ESMO 2024 showing clinical activity in MTAP-deleted pancreatic, NSCLC, and mesothelioma cancers, and the company's collaboration with Verastem Oncology to evaluate TNG456 in combination with avutometinib and defactinib in KRAS G12C mutant cancers announced in 2024.
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
Tango Therapeutics Announces Proposed $500 Million Public Offering
Tango Therapeutics stock soars on promising pancreatic cancer data
Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday
Tango Therapeutics' pancreatic cancer drug combo shows promise in study
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Massachusetts Financial Services Co. MA Acquires New Shares in Tango Therapeutics, Inc. $TNGX
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $961,500.00 in Stock
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge
Adam Crystal Sells 12,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock